Laurence Charney Biography and Net Worth

Director of TG Therapeutics

Laurence N. Charney, 76, has served on our Board since April 2012. Since 2007, Mr. Charney has served as a business strategist and financial advisor to Boards, CEOs and investors. Previously, from 1970 through June 2007, Mr. Charney was a senior audit partner at Ernst & Young, LLP, a registered public accounting firm, retiring as a practice leader in the Americas Quality and Risk Management Group. Mr. Charney currently serves as a director and audit committee chairman of Kenon Holdings Ltd. In addition, Mr. Charney previously served as a director and audit committee member of Pacific Drillings S.A, Marvel Entertainment, Inc., and other growth-oriented companies. In addition to his extensive experience on the boards of various corporate entities, Mr. Charney is also very active on the boards of several non-profit organizations. Mr. Charney graduated with a B.B.A. degree from Hofstra University and completed the Executive MBA in Business program at Columbia University. Based on Mr. Charney’s financial industry experience and in-depth understanding of our business, the Board of Directors believes that Mr. Charney has the appropriate set of skills to serve as a member of the Board.

What is Laurence N. Charney's net worth?: The estimated net worth of Laurence N. Charney is at least $2.90 million as of March 12th, 2024. Mr. Charney owns 215,229 shares of TG Therapeutics stock worth more than $2,899,135 as of April 27th. This net worth evaluation does not reflect any other assets that Mr. Charney may own. Learn More about Laurence N. Charney's net worth.
How do I contact Laurence N. Charney?: The corporate mailing address for Mr. Charney and other TG Therapeutics executives is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. TG Therapeutics can also be reached via phone at (212) 554-4484 and via email at [email protected]. Learn More on Laurence N. Charney's contact information.
Has Laurence N. Charney been buying or selling shares of TG Therapeutics?: Laurence N. Charney has not been actively trading shares of TG Therapeutics in the last ninety days. Most recently, Laurence N. Charney sold 22,000 shares of the business's stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a transaction totalling $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares of the company's stock, valued at $3,437,207.13. Learn More on Laurence N. Charney's trading history.
Who are TG Therapeutics' active insiders?: TG Therapeutics' insider roster includes Laurence Charney (Director), Yann Echelard (Director), Sagar Lonial (Director), Sean Power (CFO), and Michael Weiss (CEO). Learn More on TG Therapeutics' active insiders.
Are insiders buying or selling shares of TG Therapeutics?: In the last year, TG Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,013,000.00. In the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 195,868 shares worth more than $4,274,708.85. The most recent insider tranaction occured on March, 12th when Director Laurence N Charney sold 22,000 shares worth more than $351,340.00. Insiders at TG Therapeutics own 9.2% of the company. Learn More about insider trades at TG Therapeutics.
Information on this page was last updated on 3/12/2024.

Laurence N. Charney Insider Trading History at TG Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2024	Sell	22,000	$15.97	$351,340.00	215,229
1/5/2024	Sell	17,500	$19.03	$333,025.00	237,229
1/4/2023	Sell	30,000	$11.10	$333,000.00	234,729
4/4/2017	Sell	7,000	$11.17	$78,190.00

Laurence N. Charney Buying and Selling Activity at TG Therapeutics

TG Therapeutics Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Today's Range

Now: $13.47

$13.41

$14.01

50 Day Range

MA: $15.07

$13.02

$18.23

2 Week Range

Now: $13.47

$6.46

$35.67

Volume

2,840,667 shs

Average Volume

2,572,949 shs

Market Capitalization

$2.08 billion

P/E Ratio

673.84

Dividend Yield

N/A

Beta

2.3

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>